Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03HFG
|
|||
| Former ID |
DAP000740
|
|||
| Drug Name |
Fluvoxamine
|
|||
| Synonyms |
Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Approved | [1], [2] | |
| Therapeutic Class |
Antidepressants
|
|||
| Company |
IVAX Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H21F3N2O2
|
|||
| Canonical SMILES |
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
|
|||
| InChI |
1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
|
|||
| InChIKey |
CJOFXWAVKWHTFT-XSFVSMFZSA-N
|
|||
| CAS Number |
CAS 54739-18-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9774, 7979296, 11571264, 14899201, 17425133, 26751469, 39297346, 47276707, 47350437, 47425375, 48020069, 48020070, 49699379, 50002999, 50103976, 51005940, 57361188, 85788587, 90340960, 92718857, 93166767, 93310594, 96024678, 99373241, 103112227, 103214033, 103937470, 114182507, 117504588, 124749760, 124883444, 124883445, 124883446, 126628425, 126651435, 126666543, 131318468, 134338027, 134339778, 135004455, 137002947, 139157656, 143472592, 144204388, 160963524, 162182990, 163392547, 163842794, 164841793, 164841794
|
|||
| ChEBI ID |
CHEBI:5138
|
|||
| ADReCS Drug ID | BADD_D00950 | |||
| SuperDrug ATC ID |
N06AB08
|
|||
| SuperDrug CAS ID |
cas=054739183
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serotonin transporter (SERT) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | Serotonergic synapse | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | 5HT1 type receptor mediated signaling pathway | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| 5HT3 type receptor mediated signaling pathway | ||||
| 5HT4 type receptor mediated signaling pathway | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| NRF2 pathway | ||||
| Synaptic Vesicle Pathway | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7189). | |||
| REF 2 | Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36. | |||
| REF 3 | Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4. | |||
| REF 4 | Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986;30(2):143-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.